We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Dried Blood Used to Screen Newborns for Severe Immunodeficiency

By LabMedica International staff writers
Posted on 25 Aug 2010
A molecular test on dried blood spots is very sensitive for diagnosing severe combined immunodeficiency (SCID) in newborns.

The assay employs a quantitative polymerase chain reaction (PCR) for T-cell receptor excision circles (TREC), which are copies of DNA produced only by T-cells. More...
If the calculated TREC count is less than 30 copies/μL, it is associated with 100% sensitivity and 97% specificity for identifying SCID.

Severe combined immunodeficiency (SCID) represents a group of rare, sometimes fatal, congenital disorders characterized by little or no immune response. The defining feature of SCID, commonly known as "bubble boy" disease, is a defect in the specialized white blood cells (B- and T-lymphocytes). A review of the various methods used to diagnose SCID was published in the May 2010 issue of Pediatrics.

The review noted that a second blood spot study evaluated a two-tiered approach in which interleukin IL-7 was measured first using an enzyme-linked immunosorbent assay (ELISA), and then TRECs from those with elevated IL-7 levels, which occurs in the absence of T-cells. This study included samples from 13 children with SCID and 183 anonymized dried blood spots. For the first tier (IL-7 measurement) they calculated 96.1% specificity and 85% sensitivity (confidence interval: 55%–98%); for the second tier (TREC count) they calculated a specificity of 92.3% and a sensitivity that "approaches 100%.” If the more stringent standard of undetectable TRECs is used as a positive test result, they calculated a false-positive rate of 1.5% among children discharged from routine nurseries and 5% among children from special-care nurseries.

The study reported that on whole blood samples from infants with a median age of four months, lymphocyte counts that were less than 2.8 x 109/L had a sensitivity of 86% and a specificity of 94% for detecting SCID. From another study, they determined that among infants with a median age of 84 days, lymphocyte counts that were less than 5,000/μL had a sensitivity of only 56%, but a specificity of 100%, for detecting SCID.

Ellen A. Lipstein, M.D., M.P.H. of the MassGeneral Hospital for Children, (Boston, MA, USA), said, "The development of methods to screen for SCID by using dried blood spots, in contrast to using lymphocyte counts, which require whole blood, improves the feasibility of instituting SCID screening within current programs."

Related Links:
MassGeneral Hospital for Children




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.